The authors address an important area in terms of attitudes and beliefs that may influence treatment decisions among newly diagnosed African American breast cancer (patients) survivors. The authors support previous researchers by pointing out the fact that research on the construct of cancer fatalism among persons diagnosed with cancer is sparse, as much of the research on this topic has focused on noncancer participants and the influence of cancer fatalism on screening behaviors [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Findings from this study raise the question of whether the philosophical underpinnings of fatalism, as it relates to screening, change or are perhaps different once an individual becomes a survivor. It has been shown that perceptions of cancer fatalism are not an "all or none phenomenon" and in fact, it may be the strength of these perceptions that influenced screening behaviors as opposed to their presence or absence [8] .
Philosophically, it seems that once an individual is diagnosed with cancer and becomes a survivor, the belief that "death from cancer is inevitable" could be perceived differently and the influence of these perceptions on treatment decisions needs to be evaluated from that perspective. In fact, survivors were asked about their views about cancer fatalism before their diagnosis and these responses were compared to their current perceptions about cancer. These survivors showed a significant decrease in fatalistic perceptions about cancer [11] . However, these survivors were on average, five or more years postdiagnosis and perceptions about treatment decisions based on these beliefs were not assessed.
As we move forward with these types of discussions, I think we must ensure we are comparing the same phenomena. It may be premature to use the same definitions and instruments (modified) to categorize fatalism for newly diagnosed survivors and then suggest these perceptions influence their cancer-related treatment decisions prior to these types of philosophical inquiries. More research is needed to understand not only attitudes and beliefs, including fatalism, among survivors, but more importantly, potential interactions of these types of variables, their influence on treatments, and their role in the survivorship experience for African Americans. I look forward to additional findings from these researchers on the development of specific measures of "fatalism specific to treatment" and whether these types of attitudes and beliefs coupled with other variable help us understand how to retain African American women in treatment. In addition, it will be important to note whether fatalism about treatment varies by age, stage of disease, and length of survivorship and lastly, whether these types of perceptions vary in those that treatment adherence or follow-up rates. Clearly, the goal is to understand factors that influence the cancer experience for African American women so that we can develop interventions to help them address any unmet needs. I applaud these authors for their continued work in this important area.
